About: Repurposing Pyramax®, Quinacrine and Tilorone as Treatments for Ebola Virus Disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Repurposing Pyramax®, Quinacrine and Tilorone as Treatments for Ebola Virus Disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Repurposing Pyramax®, Quinacrine and Tilorone as Treatments for Ebola Virus Disease
Creator	Holbrook, Michael Dyall, Julie Zhou, Huanying Postnikova, Elena Ekins, Sean Liang, Janie Lane, Thomas Liang, E Madrid, Peter Zhou, C Foil, Daniel Goodin, Caleb Goodin, L Holbrook, J Madrid, M Mercer, J Mercer, Luke Pyramax®, Repurposing
Source	Elsevier; Medline; PMC
abstract	Abstract We have recently identified three molecules (tilorone, quinacrine and pyronaridine tetraphosphate) which all demonstrated efficacy in the mouse model of infection with mouse-adapted Ebola virus (EBOV) model of disease and had similar in vitro inhibition of an Ebola pseudovirus (VSV-EBOV-GP), suggesting they interfere with viral entry. Using a machine learning model to predict lysosomotropism these compounds were evaluated for their ability to possess a lysosomotropic mechanism in vitro. We now demonstrate in vitro that pyronaridine tetraphosphate is an inhibitor of Lysotracker accumulation in lysosomes (IC50 = 0.56 μM). Further, we evaluated antiviral synergy between pyronaridine and artesunate (Pyramax®), which are used in combination to treat malaria. Artesunate was not found to have lysosomotropic activity in vitro and the combination effect on EBOV inhibition was shown to be additive. Pyramax® may represent a unique example of the repurposing of a combination product for another disease.
has issue date	2020-08-13(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2020.104908
bibo:pmid	32798602
has license	els-covid
sha1sum (hex)	67301f02784dc83fd22109641da4aa326f041ef5
schema:url	https://doi.org/10.1016/j.antiviral.2020.104908
resource representing a document's title	Repurposing Pyramax®, Quinacrine and Tilorone as Treatments for Ebola Virus Disease
has PubMed Central identifier	PMC7425680
has PubMed identifier	32798602
schema:publication	Antiviral Research
resource representing a document's body	covid:67301f02784dc83fd22109641da4aa326f041ef5#body_text
is schema:about of	named entity 'demonstrated' named entity 'pyronaridine' named entity 'Virus' named entity 'Disease' named entity 'Short' named entity 'INHIBITION' named entity 'Ebola' named entity 'identified' named entity 'chloroquine' named entity 'infection' named entity 'guinea pig' named entity 'EBOV' named entity 'antiviral' named entity 'EBOV' named entity 'amphiphilic' named entity 'probability' named entity 'tilorone' named entity 'drug metabolism' named entity 'artesunate' named entity 'fetal bovine serum' named entity 'molecule' named entity 'Assay' named entity 'pyronaridine' named entity 'approved drugs' named entity 'Git' named entity 'lysosomal' named entity 'ThermoFisher' named entity 'Montreal' named entity 'tilorone' named entity 'Madrid' named entity 'Vero cells' named entity 'antivirals' named entity 'EBOV' named entity 'synergistic' named entity 'EVD' named entity 'Madrid' named entity 'Democratic Republic of the Congo' named entity 'Madrid' named entity 'malaria' named entity 'cell death' named entity 'PBS' named entity 'acid sphingomyelinase' named entity 'pKa' named entity 'artesunate' named entity 'cholesterol' named entity 'ATCC' named entity 'pyronaridine' named entity 'quinacrine' named entity 'viral entry' named entity 'quinacrine' named entity 'mouse model' named entity 'VSV-EBOV' named entity 'treatment for Ebola' named entity 'Quinacrine' named entity 'EBOV' named entity 'endosomes' named entity 'EBOV' named entity 'pyronaridine' named entity 'EBOV' named entity 'high throughput' named entity 'quinacrine' named entity 'correlation' named entity 'clinical trial' named entity 'quinacrine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software